MESO
$14.53
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based ...
Recent News
Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Ryoncil 2026 Revenue Guidance – Has The Bull Case Changed?
Mesoblast recently reported half-year 2026 results showing revenue of US$51.34 million versus US$3.16 million a year earlier, with net loss narrowing to US$40.16 million, and issued full‑year 2026 Ryoncil net revenue guidance of US$110 million to US$120 million. The update highlighted growing commercial traction for Ryoncil, including broad U.S. reimbursement coverage and expanding transplant centre adoption, alongside continued investment in late‑stage cell therapy programs. We’ll now...
Mesoblast H1 Earnings Call Highlights
Mesoblast (NASDAQ:MESO) executives highlighted strong early commercial momentum for its cell therapy Ryoncil and outlined multiple regulatory and clinical milestones ahead during the company’s financial results call for the half year ended Dec. 31, 2025. Ryoncil launch drives first-half revenue Chi
ASX Growth Companies With High Insider Stakes To Watch
As the Australian market faces a slightly lower opening amid global tech sector challenges, investors are increasingly cautious, influenced by Wall Street's recent downturn and upcoming central bank meetings. In this climate, growth companies with high insider ownership can be particularly appealing as they often signal strong internal confidence and alignment with shareholder interests.
ASX Penny Stocks To Watch In January 2026
As the Australian market navigates a week marked by geopolitical tensions and mixed economic data, investor sentiment remains cautious. Despite this hesitancy, there is still interest in exploring opportunities within the realm of penny stocks, which often represent smaller or newer companies with potential for growth. While the term "penny stocks" may seem outdated, these investments can offer a unique blend of affordability and potential when supported by strong financials.
Markets in a Minute: Mesoblast, Alkane Resources shine
The ASX200 is up around .2 of a per cent at around lunchtime, led by strong gains from the energy sector and consumer staples. Gold is trading just below USD 4470 an ounce, whilst silver is at USD 77 an ounce. Green Mesoblast is up after reporting US$35.1 million in revenue from Ryoncil sales for the December quarter — a 60% increase on the previous period, driven by strong demand for its cell therapy treatment. Alkane Resources also shot up after posting gold equivalent production of 43,663 ounces in the December quarter, with output from gold and antimony across its three mines supporting a solid operational performance. Red Rio Tinto is down after confirming early-stage merger talks with Glencore. The deal, if it proceeds, could involve an all-share acquisition of Glencore via a court-approved scheme of arrangement. European Lithium is down despite confirming construction is now underway at the Tanbreez rare earths project in southern Greenland, following formal approval by Critical Metals Corp. #ASX200 #StockMarketUpdate #GoldPrices #SilverPrices #Mesoblast #BiotechStocks #CellTherapy #AlkaneResources #GoldMining #RareEarths #EuropeanLithium #TanbreezProject #RioTinto #Glencore